US · Healthcare · Biotechnology
EPS came in at -0.76 against a street estimate of -0.76 — a beat of 0.0%.
Analysts rate Maze Therapeutics, Inc. Common Stock a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $62.54.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 9.06% |
| TRV GP IV, LLC | 8.05% |
| ARCH VENTURE CORP | 7.42% |
| Deep Track Capital, LP | 6.72% |
| BlackRock Inc | 6.31% |
| Jupiter Topco LLC | 6.14% |
| T. Rowe Price Investment Management,Inc. | 4.69% |
| Logos Global Management LP | 3.48% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • On October 15, 2026, Maze Therapeutics exchanged 2,776,007 shares of common stock held by Frazier Life Sciences entities for pre-f | 2026-10-16 |
| Board / officer change · Q3 2026 MAZE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Two new board directors appointed effective August 13, 2026 • Each director granted 36,000 | 2026-08-17 |
| Quarterly report · Q2 2026 MAZE THERAPEUTICS, INC. – SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $202.6 million in cash and cash equivalents; $494.9 million | 2026-08-11 |
| Results announced · Q3 2026 MAZE THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $494.9 million as of June 30, 2026, up from $360.0 million at December | 2026-08-11 |
| Shareholder vote results · Q2 2026 MAZE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • 44,660,029 shares represented at Annual Meeting (89.75% of total outstanding shares entitle | 2026-06-10 |
| Board / officer change · Q2 2026 MAZE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial metrics disclosed in this filing • Filing date: May 22, 2026 • Company trades | 2026-05-22 |
| Quarterly report · Q1 2026 MAZE THERAPEUTICS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Cash position: $198.8 mil | 2026-05-12 |
| Proxy statement · Q2 2026 MAZE THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Class I Directors – Elect Jason Col | 2026-04-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 2 trials expected to initiate in 2026; topline data expected Q1 2026 Maze Therapeutics, a clinical-stage biotech company, reported Q3 2025 results with several positive developments. The company announced promising first-in-human Phase 1 data for MZE782, show | 2025-11-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Maze Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.